Cordgenics ChemoID (chemo sensitivity)

Tests chemotherapy drugs directly on a patient's fresh tumor tissue to see which ones the cancer responds to.

Vetted listing

Testing

Consented intake · your records travel with you · nothing moves without your sign-off

Why Cordgenics exists

Cordgenics ChemoID is a functional test that applies drugs to fresh tumor tissue and observes the response, with turnaround from two days to six weeks. It is designed to give greater confidence that a patient will respond to a drug or combination before treatment begins. Obtaining fresh tumor tissue can be a limitation, which patients should plan for.

CLIA certified and CAP accredited assayFDA Breakthrough Device Designation

Prefer the source? Cordgenics ChemoID (chemo sensitivity)'s own site has more.

Share your records

We'll pre-fill the intake from your records — no retyping.

Start sharing →

Check your coverage

See if your insurance covers this and estimate out-of-pocket cost.

Check coverage →

Coverage, insurance & cost

The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how Cordgenics ChemoID (chemo sensitivity) handles billing.

We don't have confirmed insurance details for Cordgenics ChemoID (chemo sensitivity) yet. Start a coverage check with your plan, or contact the provider directly.

Understand this before you decide

For Patients

Guide from Cordgenics ChemoID (chemo sensitivity)

FAQ

Guide from Cordgenics ChemoID (chemo sensitivity)

Ask about this service

Answers grounded in Cordgenics's details here. Educational only; your oncologist directs treatment.

Ask OpenCancer · answers grounded in this storefront

Who this is for

Cancer types served

brainovarian

Also consider

Other providers in similar categories.

BostonGene

6 offerings

Gather distinctive biomarkers that can guide treatment and monitor disease progression

Foundation Medicine

6 offerings

FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.